2019
Specific sequences of infectious challenge lead to secondary hemophagocytic lymphohistiocytosis-like disease in mice
Wang A, Pope SD, Weinstein JS, Yu S, Zhang C, Booth CJ, Medzhitov R. Specific sequences of infectious challenge lead to secondary hemophagocytic lymphohistiocytosis-like disease in mice. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 2200-2209. PMID: 30674681, PMCID: PMC6369774, DOI: 10.1073/pnas.1820704116.Peer-Reviewed Original ResearchConceptsSecondary hemophagocytic lymphohistiocytosisAssociated transcriptional programRNA sequencing analysisBone marrow-derived macrophagesTranscriptional programsTranscriptional profilingMarrow-derived macrophagesBone marrow macrophagesTranscriptional profilesNonlethal doseMitochondrial functionToll-like receptor agonistsSequencing analysisSpecific sequencesSetting of infectionGlycolytic metabolismMarrow macrophagesUseful therapeutic strategyGlycolysis inhibitorLethal stateHyperinflammatory stateHyperinflammatory responseOxidative metabolismHemophagocytic lymphohistiocytosisMortal complications
2017
JAK inhibitors in dermatology: The promise of a new drug class
Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. Journal Of The American Academy Of Dermatology 2017, 76: 736-744. PMID: 28139263, PMCID: PMC6035868, DOI: 10.1016/j.jaad.2016.12.005.Peer-Reviewed Original ResearchMeSH KeywordsAlopecia AreataAnti-Inflammatory AgentsAzetidinesClinical Trials as TopicDermatitis, AtopicDermatologic AgentsHumansJanus KinasesMolecular Targeted TherapyNitrilesPiperidinesProtein Kinase InhibitorsPsoriasisPurinesPyrazolesPyrimidinesPyrrolesSignal TransductionSkin DiseasesSulfonamidesVitiligoConceptsJAK inhibitorsSoluble inflammatory mediatorsNew drug classesUseful therapeutic strategyDifferent proinflammatoryAtopic dermatitisInflammatory mediatorsInflammatory dermatosesAlopecia areataDrug classesJanus kinase-signal transducerTherapeutic strategiesJAK inhibitionDermatologic therapyKinase-signal transducerTargeted therapeuticsActivator of transcriptionDermatologyJAK-STATInhibitorsPromising new classEarlier reportsInhibition
2011
Studies of Vascular Endothelial Growth Factor in Asthma and Chronic Obstructive Pulmonary Disease
Lee CG, Ma B, Takyar S, Ahangari F, DelaCruz C, He CH, Elias JA. Studies of Vascular Endothelial Growth Factor in Asthma and Chronic Obstructive Pulmonary Disease. Annals Of The American Thoracic Society 2011, 8: 512-515. PMID: 22052929, PMCID: PMC3359071, DOI: 10.1513/pats.201102-018mw.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorRIG-like helicaseTh2 inflammationEndothelial growth factorImmune pathwaysVirus-induced COPD exacerbationsChronic obstructive pulmonary diseaseViral pathogen-associated molecular patternsRole of VEGFGrowth factorDendritic cell activationObstructive pulmonary diseaseAbrogation of VEGFInnate immune pathwaysUseful therapeutic strategyVEGF receptor blockadePathogen-associated molecular patternsTissue responseCOPD exacerbationsMucus metaplasiaEosinophilic inflammationReceptor blockadePulmonary diseaseSubepithelial fibrosisCytokine elaboration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply